As the United States grapples with significant drug shortages and a growing backlog of medical needs, Indian pharmaceutical companies are positioned to capitalize on this emerging market opportunity. Industry analysts are optimistic about India’s potential growth, especially with numerous key drugs slated to lose patent protection between 2025 and 2029, paving the way for an increase in generic drug production.
The inauguration of Donald Trump as President is anticipated to further bolster India’s pharmaceutical sector. The US, which accounts for approximately 30% of India’s pharmaceutical exports, presents a critical market for Indian companies. With the US facing acute shortages, there is a unique opportunity for Indian manufacturers to step in and bridge the gap.
India’s reputation as a major supplier of generic drugs is well established, underscored by the country hosting the largest number of US FDA-approved manufacturing plants outside of the United States. According to Sudharshan Jain, General Secretary of the Indian Pharmaceutical Alliance, this is a testament to India’s commitment to meeting global demands for essential medications.Financial figures underscore this growth trajectory, with exports to the US climbing to $8.7 billion in FY24 from $7.5 billion the previous fiscal year, as reported by the Directorate General of Commercial Intelligence and Statistics.
The Trump administration is expected to ease trade restrictions, which industry experts believe will favour the Indian generics market. This shift could be strategically significant, especially considering that 87% of FDA-registered Active Pharmaceutical Ingredient (API) plants are located abroad, predominantly in China, which dominates this sector. India, which sources about 70% of its APIs from China, stands to benefit from any changes in trade policies that affect Chinese exports.Furthermore, any tariffs imposed on Chinese goods could present an advantage for Indian API manufacturers, placing them in a favourable position to increase their market share in the US.
Shriram Subramanian, Managing Director of inGovern Research Services, suggests that pharmaceutical leaders are closely monitoring the health sector reforms proposed by the Trump administration, which could reshape global supply chains and open new avenues for Indian pharmaceutical companies.
Thus, the evolving dynamics of the US pharmaceutical market, coupled with administrative changes, hold promising prospects for India’s drug makers. The nation’s established infrastructure, coupled with strategic policy adaptations, could significantly enhance its role as a global pharmaceutical hub.
– Dr.Jagan Mohan Somagoni
